Payment overview · 2025
General Payments
$627.13
29 reported records · 11 companies
Healthcare provider profile · identity verified
Thomas C Selvaggi, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COMMERCE, TX · NPI 1255326393
Verified facts
What the public records show
CMS Open Payments records show Thomas C Selvaggi, M.D. received $627.13 in general payments during 2025 across 29 reported records.
ABBVIE INC. accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rexulti, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 747 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $158.16 | 25.2% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $101.32 | 16.2% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $92.88 | 14.8% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.65 | 11.9% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $42.63 | 6.8% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $38.62 | 6.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.24 | 6.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.51 | 5.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.48 | 2.6% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$15.72 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.92 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $627.13 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $158.16 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $101.32 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $92.88 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $74.65 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $74.65 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $42.63 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $39.25 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $38.24 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 747 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 71 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
59 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
109 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
71 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
39 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
747 | 71 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1408 | 241 |
| Gabapentin | Gabapentin | 1092 | 159 |
| Furosemide | Furosemide | 885 | 118 |
| Potassium Chloride | Potassium Chloride | 768 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 763 | 120 |
| Eliquis | Apixaban | 747 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 737 | 115 |
| Lisinopril | Lisinopril | 529 | 95 |
| Donepezil Hcl | Donepezil Hcl | 513 | 84 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 505 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 475 | 78 |
| Losartan Potassium | Losartan Potassium | 407 | 79 |
| Sertraline Hcl | Sertraline Hcl | 393 | 48 |
| Montelukast Sodium | Montelukast Sodium | 385 | 55 |
| Trazodone Hcl | Trazodone Hcl | 384 | 67 |
| Buspirone Hcl | Buspirone Hcl | 372 | 58 |
| Omeprazole | Omeprazole | 370 | 81 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 369 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 367 | 64 |
| Spironolactone | Spironolactone | 345 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 341 | 95 |
| Myrbetriq | Mirabegron | 328 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 319 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 304 | 54 |
| Memantine Hcl | Memantine Hcl | 303 | 51 |
| Citalopram Hbr | Citalopram Hydrobromide | 299 | 46 |
| Mirtazapine | Mirtazapine | 297 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 294 | 42 |
| Carvedilol | Carvedilol | 281 | 53 |
| Tizanidine Hcl | Tizanidine Hcl | 276 | 43 |
| Metformin Hcl | Metformin Hcl | 275 | 60 |
| Alendronate Sodium | Alendronate Sodium | 258 | 44 |
| Tramadol Hcl | Tramadol Hcl | 249 | 58 |
| Meloxicam | Meloxicam | 243 | 37 |
| Alprazolam | Alprazolam | 230 | 45 |
| Divalproex Sodium | Divalproex Sodium | 226 | 42 |
| Levetiracetam | Levetiracetam | 215 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 210 | 51 |
| Jardiance | Empagliflozin | 203 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 203 | 29 |
| Januvia | Sitagliptin Phosphate | 190 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 189 | 43 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 183 | 14 |
| Finasteride | Finasteride | 183 | 22 |
| Glipizide | Glipizide | 178 | 31 |
| Xarelto | Rivaroxaban | 164 | 18 |
| Azithromycin | Azithromycin | 158 | 84 |
| Diclofenac Sodium | Diclofenac Sodium | 153 | 48 |
| Baclofen | Baclofen | 152 | 22 |
| Lorazepam | Lorazepam | 150 | 27 |
| Risperidone | Risperidone | 139 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 139 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 134 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 30 |
| Allopurinol | Allopurinol | 133 | 22 |
| Enulose | Lactulose | 132 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 131 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 130 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 124 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 123 | 66 |
| Ondansetron Hcl | Ondansetron Hcl | 123 | 71 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 123 | 73 |
| Fluconazole | Fluconazole | 122 | 54 |
| Ezetimibe | Ezetimibe | 121 | 21 |
| Simvastatin | Simvastatin | 112 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 28 |
| Farxiga | Dapagliflozin Propanediol | 109 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 106 | 14 |
| Trulicity | Dulaglutide | 106 | suppressed |
| Fentanyl | Fentanyl | 105 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 105 | 14 |
| Latanoprost | Latanoprost | 103 | 14 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 95 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 91 | 26 |
| Pregabalin | Pregabalin | 91 | 18 |
| Albuterol Sulfate | Albuterol Sulfate | 90 | 29 |
| Sucralfate | Sucralfate | 87 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 36 |
| Bupropion Hcl Sr | Bupropion Hcl | 86 | 12 |
| Famotidine | Famotidine | 84 | 18 |
| Ceftriaxone | Ceftriaxone Sodium | 79 | 47 |
| Benztropine Mesylate | Benztropine Mesylate | 78 | suppressed |
| Clonazepam | Clonazepam | 78 | 18 |
| Levofloxacin | Levofloxacin | 76 | 49 |
| Warfarin Sodium | Warfarin Sodium | 76 | suppressed |
| Gemtesa | Vibegron | 73 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 70 | 51 |
| Lactulose | Lactulose | 69 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 34 |
| Aripiprazole | Aripiprazole | 62 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 61 | 15 |
| Prednisone | Prednisone | 61 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 27 |
| Lidocaine Hcl | Lidocaine Hcl | 60 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 11 |
| Linzess | Linaclotide | 59 | 11 |
| Nifedipine Er | Nifedipine | 59 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | suppressed |
| Tradjenta | Linagliptin | 58 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 57 | 24 |
| Metronidazole | Metronidazole | 55 | 26 |
| Ertapenem | Ertapenem Sodium | 53 | 24 |
| Lithium Carbonate | Lithium Carbonate | 51 | suppressed |
| Mupirocin | Mupirocin | 51 | 35 |
| Venlafaxine Hcl | Venlafaxine Hcl | 51 | suppressed |
| Budesonide | Budesonide | 50 | 12 |
| Pentoxifylline | Pentoxifylline | 50 | suppressed |
| Bumetanide | Bumetanide | 49 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 49 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 48 | 13 |
| Restasis | Cyclosporine | 48 | suppressed |
| Olanzapine | Olanzapine | 47 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 46 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 46 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 45 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 12 |
| Bupropion Hcl | Bupropion Hcl | 44 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 12 |
| Methocarbamol | Methocarbamol | 44 | 16 |
| Novolin R Flexpen | Insulin Regular, Human | 44 | suppressed |
| Cephalexin | Cephalexin | 43 | 19 |
| Megestrol Acetate | Megestrol Acetate | 43 | suppressed |
| Digoxin | Digoxin | 42 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 42 | suppressed |
| Timolol Maleate | Timolol Maleate | 42 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | suppressed |
| Amoxicillin | Amoxicillin | 41 | 34 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 31 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 40 | suppressed |
| Nystatin | Nystatin | 40 | 24 |
| Primidone | Primidone | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 39 | 37 |
| Divalproex Sodium Er | Divalproex Sodium | 39 | suppressed |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 37 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 36 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 36 | suppressed |
| Ketoconazole | Ketoconazole | 36 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 36 | 18 |
| Vascepa | Icosapent Ethyl | 36 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 35 | suppressed |
| Novolin R | Insulin Regular, Human | 34 | suppressed |
| Vraylar | Cariprazine Hcl | 34 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 33 | 20 |
| Nyamyc | Nystatin | 33 | 20 |
| Verapamil Hcl | Verapamil Hcl | 33 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Ingrezza | Valbenazine Tosylate | 31 | suppressed |
| Buprenorphine | Buprenorphine | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Renvela | Sevelamer Carbonate | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Armour Thyroid | Thyroid,pork | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 22 |
| Ozempic | Semaglutide | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Tobramycin | Tobramycin | 27 | 21 |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Humulin R | Insulin Regular, Human | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Fluorometholone | Fluorometholone | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Leflunomide | Leflunomide | 23 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 23 | 17 |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Xifaxan | Rifaximin | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 22 | suppressed |
| Levemir | Insulin Detemir | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Verapamil Sr | Verapamil Hcl | 22 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Cefdinir | Cefdinir | 20 | 15 |
| Rivastigmine | Rivastigmine Tartrate | 20 | suppressed |
| Lumigan | Bimatoprost | 19 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | 13 |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 17 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 12 |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 13 |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Rifampin | Rifampin | 16 | 14 |
| Simbrinza | Brinzolamide/Brimonidine Tart | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Humira Pen | Adalimumab | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Linezolid | Linezolid | 13 | 13 |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Rhopressa | Netarsudil Mesylate | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Budesonide Dr | Budesonide | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Bacitracin-Polymyxin | Bacitracin/Polymyxin B Sulfate | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Daptomycin | Daptomycin | 11 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $627.13 · 29 records | ABBVIE INC. | AREXVY, AUSTEDO XR, BREZTRI, CAPLYTA, ELIQUIS, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error